^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY2701439

    i
    Other names: BAY2701439, BAY 2701439, thorium-227 labeled antibody-chelator conjugate, HER2-TTC, BAY-2701439
    Company:
    Bayer
    Drug class:
    HER2 inhibitor, Alpha radiation emitter
    Related drugs:
    2years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=14, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439
    2years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Bayer | Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Mar 2024 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439
    over2years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | N=213 --> 14 | Trial completion date: Jul 2028 --> Apr 2024 | Trial primary completion date: Jul 2026 --> Mar 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439
    over3years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=213, Recruiting, Bayer | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    over4years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=213, Recruiting, Bayer | Trial completion date: Sep 2026 --> Jul 2027 | Trial primary completion date: Dec 2024 --> Jul 2025
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    over5years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1;Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    over5years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=176, Not yet recruiting, Bayer | Initiation date: Mar 2020 --> Sep 2020
    Clinical • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    almost6years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=176, Not yet recruiting, Bayer | Trial completion date: May 2027 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Oct 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438
    6years
    A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
    P1, N=176, Not yet recruiting, Bayer
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
    |
    BAY2701439 • BAY2701438